The Responsiveness of the Overactive Bladder Questionnaire (OAB-q)

Overview

Journal Qual Life Res

Specialties Pharmacology
Rehabilitation Medicine

Date 2005 Jul 19

PMID 16022077

Citations 40

Authors

Karin S Coyne

Louis S Matza

Christine L Thompson

Affiliations

Soon will be listed here.

Abstract

Purpose: The purpose of this study was to examine the responsiveness of the Overactive Bladder questionnaire (OAB-q) during anti-muscarinic treatment.

Methods: OAB patients were treated with tolterodine ER 4 mg/day for 12 weeks. The OAB-q and 3-day micturition diaries were collected at baseline, 4, and 12 weeks. The patients' and physicians' perceptions of treatment benefit were assessed at 4 and 12 weeks. Responsiveness of the OAB-q was examined with effect sizes and comparisons to other measures using ANOVAs, t-tests, and correlations.

Results: A total of 865 patients completed the 12-week study (mean age 61 years; 73% female; 89% Caucasian). From baseline to 4 weeks, significant improvements (p < 0.0001) occurred in all OAB-q subscales, which were maintained through week 12. The OAB-q was highly responsive with subscale effect sizes ranging from 0.44 (social interaction) to 1.2 (symptom bother). Significant score changes in all OAB-q subscales (p < 0.05) were associated with reductions of > or = 3 urgency episodes, > or = 3 micturitions, or > or = 1 incontinence episode per day. Improvements in OAB-q scales were associated with changes in patient and physician perceptions of treatment benefit.

Conclusions: The OAB-q was highly responsive and demonstrated responsiveness to reductions in urinary urgency, frequency, and incontinence during antimuscarinic treatment of OAB. The OAB-q appears to be a useful outcome measure for treatments of OAB.

Citing Articles

Efficacy and safety of non-invasive low-frequency tibial nerve stimulator in overactive bladder.

Zhang Z, Liu M, Wang Y, Wu P, Zhu Y, Han B Eur J Med Res. 2025; 30(1):40.

PMID: 39833952 PMC: 11748249. DOI: 10.1186/s40001-024-02262-z.

The effect of pelvic floor muscle training in men with benign prostatic hyperplasia and overactive bladder.

Hagovska M, Svihra Sr J, Macko L, Jr J, Svihra Jr J, luptak J World J Urol. 2024; 42(1):287.

PMID: 38698269 PMC: 11065782. DOI: 10.1007/s00345-024-04974-7.

Trial Design for Mixed Urinary Incontinence: Midurethral Sling Versus Botulinum Toxin A.

Harvie H, Richter H, Sung V, Chermansky C, Menefee S, Rahn D Urogynecology (Phila). 2024; 30(5):478-488.

PMID: 38212101 PMC: 11058039. DOI: 10.1097/SPV.0000000000001422.

Cannabis and cannabinoids for symptomatic treatment for people with multiple sclerosis.

Filippini G, Minozzi S, Borrelli F, Cinquini M, Dwan K Cochrane Database Syst Rev. 2022; 5:CD013444.

PMID: 35510826 PMC: 9069991. DOI: 10.1002/14651858.CD013444.pub2.

Evaluation of Silodosin and Pelvic Floor Muscle Training in Men with Benign Prostatic Hyperplasia and Overactive Bladder (Silodosing) Study Protocol (Spirit Compliant).

Hagovska M, Svihra J Int J Environ Res Public Health. 2021; 18(21).

PMID: 34769943 PMC: 8582742. DOI: 10.3390/ijerph182111426.

References

Deyo R, Centor R . Assessing the responsiveness of functional scales to clinical change: an analogy to diagnostic test performance. J Chronic Dis. 1986; 39(11):897-906. DOI: 10.1016/0021-9681(86)90038-x. View

Sprangers M, Moinpour C, Moynihan T, Patrick D, Revicki D . Assessing meaningful change in quality of life over time: a users' guide for clinicians. Mayo Clin Proc. 2002; 77(6):561-71. DOI: 10.4065/77.6.561. View

Stewart W, Van Rooyen J, Cundiff G, Abrams P, Herzog A, Corey R . Prevalence and burden of overactive bladder in the United States. World J Urol. 2003; 20(6):327-36. DOI: 10.1007/s00345-002-0301-4. View

Leidy N, Revicki D, Geneste B . Recommendations for evaluating the validity of quality of life claims for labeling and promotion. Value Health. 2006; 2(2):113-27. DOI: 10.1046/j.1524-4733.1999.02210.x. View

Coyne K, Revicki D, Hunt T, Corey R, Stewart W, Bentkover J . Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: the OAB-q. Qual Life Res. 2002; 11(6):563-74. DOI: 10.1023/a:1016370925601. View

Liberman J, Hunt T, Stewart W, Wein A, Zhou Z, Herzog A . Health-related quality of life among adults with symptoms of overactive bladder: results from a U.S. community-based survey. Urology. 2001; 57(6):1044-50. DOI: 10.1016/s0090-4295(01)00986-4. View

Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U . The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Am J Obstet Gynecol. 2002; 187(1):116-26. DOI: 10.1067/mob.2002.125704. View

Kazis L, Anderson J, Meenan R . Effect sizes for interpreting changes in health status. Med Care. 1989; 27(3 Suppl):S178-89. DOI: 10.1097/00005650-198903001-00015. View

Siami P, Seidman L, Lama D . A multicenter, prospective, open-label study of tolterodine extended-release 4 mg for overactive bladder: the speed of onset of therapeutic assessment trial (STAT). Clin Ther. 2002; 24(4):616-28. DOI: 10.1016/s0149-2918(02)85137-2. View

10.

Revicki D, Osoba D, Fairclough D, Barofsky I, BERZON R, Leidy N . Recommendations on health-related quality of life research to support labeling and promotional claims in the United States. Qual Life Res. 2001; 9(8):887-900. DOI: 10.1023/a:1008996223999. View

11.

Guyatt G, Walter S, Norman G . Measuring change over time: assessing the usefulness of evaluative instruments. J Chronic Dis. 1987; 40(2):171-8. DOI: 10.1016/0021-9681(87)90069-5. View

12.

Milsom I, Abrams P, Cardozo L, Roberts R, Thuroff J, Wein A . How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int. 2001; 87(9):760-6. DOI: 10.1046/j.1464-410x.2001.02228.x. View

13.

Kelleher C, Reese P, Pleil A, Okano G . Health-related quality of life of patients receiving extended-release tolterodine for overactive bladder. Am J Manag Care. 2003; 8(19 Suppl):S608-15. View

14.

Jackson S . The patient with an overactive bladder--symptoms and quality-of-life issues. Urology. 1998; 50(6A Suppl):18-22; discussion 23-4. DOI: 10.1016/s0090-4295(97)00580-3. View

15.

Hays R, Hadorn D . Responsiveness to change: an aspect of validity, not a separate dimension. Qual Life Res. 1992; 1(1):73-5. DOI: 10.1007/BF00435438. View